Table 3.

IO/RT clinical trials^* in metastatic breast cancer

Sponsor	Phase	N	Tumor type	Intervention
Abramson Cancer Center of the University of Pennsylvania (NCT02639026)	1	30	Multiple tumor types, including BC	MEDI4736 and tremelimumab + hypofractionated RT (24 Gy in 3 fractions or 17 Gy in 1 fraction)
Kyoto University Hospital, Japan (NCT03430479)	1, 2	32	HR+/HER2− mBC	Nivolumab and hormone therapy + RT
RACHEL1: MD Anderson Cancer Center (NCT03524170)	1	20	HR+/HER2− mBC	M7824 (Anti-PDL1/TGF-beta trap) + RT
Houston Methodist Cancer Center (NCT03004183)	2	57	mTNBC or lung cancer	ADV/HSV-tk and valacyclovir and pembrolizumab + SBRT (30 Gy in 5 fractions)
Peter MacCallum Cancer Centre, Australia, Trans-Tasman Radiation Oncology Group (TROG) (NCT03464942)	2	52	mTNBC	Atezolizumab + SBRT (20 Gy in 1 fraction or 24 Gy in 3 fractions)
Institut Bergoni, Roche Pharma AG, National Cancer Institute, France (NCT03915678)	2	247	Multiple tumor types, including mTNBC	Atezolizumab and G100 + short-course RT (4 Gy in 2 fractions) or SBRT (27 Gy to 60 Gy in 3–5 fractions)
Memorial Sloan Kettering Cancer Center (NCT02563925)	1	28	mBC with CNS metastases	Tremelimumab and HER2-directed therapy and durvalumab + WBRT or SRS
Dana-Farber Cancer Institute (NCT03483012)	2	45	TNBC with CNS metastases	Atezolizumab + SRS
Weill Cornell (NCT03449238)	1, 2	41	mBC with CNS metastases	Pembrolizumab + SRS
H. Lee Moffitt Cancer Center and Research Institute (NCT03807765)	1	12	mBC with CNS metastases	Nivolumab + SRS

Abbreviations: CNS = central nervous system; HR+/HER2− = hormone receptor positive/human estrogen receptor 2 negative; IMRT = intensity modulated radiation therapy; mBC = metastatic breast cancer; mTNBC = metastatic triple negative breast cancer; RT = radiation therapy; SBRT = stereotactic body radiation therapy; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy.

^*Registered on clinicaltrials.gov of April 1, 2020.